First AD

Second AD

Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

Video content above is prompted by the following:

There are many ongoing frontline combination studies in CLL, and

what are your impressions of the arm D – zanu plus venetoclax data in the SEQUOIA trial?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Updates in the Treatment of CLL  

Peer Exchange

Panelists discuss how the combination of zanubrutinib plus venetoclax in arm D of the SEQUOIA trial contributes to understanding the potential role of BTK inhibitor and BCL2 inhibitor combinations in frontline CLL treatment.